Voriconazole

Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha sterol demethylase makes it useful against some fluconazole-resistant organisms. Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002.

Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha sterol demethylase makes it useful against some fluconazole-resistant organisms. Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002.

For the treatment of esophageal candidiasis, cadidemia, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.

• Aspergillosis of the Central Nervous System
• Aspergillosis of the Liver
• Candidemia
• Candidiasis
• Coccidioidomycosis
• Endocarditis caused by Aspergillus
• Esophageal Candidiasis
• Fungal Infections
• Fungal meningitis caused by Exserohilum Infection
• Fusarium infection
• Histoplasmosis
• Invasive Aspergillosis
• Osteomyelitis caused by Aspergillus
• Penicillium marneffei infection
• Peritonitis caused by Aspergillus
• Scedosporium Infection
• Sinusitis aspergillus
• Aspergillus endophthalmitis
• Refractory Oral Candidiasis